United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript
United Therapeutics (NASDAQ: UTHR) reported Q2 2026 revenues of $783.3 million, down 2% year over year, and net income per diluted share of $7.27 versus $6.41. Tyvaso DPI sales were $326.6 million, while nebulized Tyvaso fell 18% to $126.0 million. Management discussed a path to a $4 billion 2027 revenue run rate amid competitive pressure and upcoming IPF and PAH launches.
How this was made
The 30-second read
Why it matters
The most tradable elements are the quantified segment performance (including nebulized Tyvaso decline), the sales force expansion timing, and the stated regulatory submission and potential review timelines for 2027 approvals.
Market read
Traders can update expectations for 2027 catalyst timing (Tyvaso IPF, ralinepag PAH, and SMI device) and weigh them against ongoing competitive pressure in nebulized Tyvaso and a narrowed $4B run-rate trajectory.
What to watch
Tyvaso IPF launch is initially limited to the nebulized formulation, and the transcript flags ongoing FDA discussions for bridging requirements, which could delay or constrain uptake versus a full device rollout.
Background
This is a Q2 2026 corporate update earnings call transcript for United Therapeutics, covering financials, commercial execution, and regulatory and clinical pipeline milestones.
Ticker impact
United Therapeutics reported Q2 2026 results and reiterated a path to a $4B 2027 revenue run rate, alongside Tyvaso IPF and ralinepag PAH NDA timelines.
Likely two-sided reaction: upside from clearer 2027 approval cadence and sales force expansion, offset by continued weakness in nebulized Tyvaso quantities and narrowed $4B run-rate path.
The transcript includes multiple concrete datapoints (revenue, segment trends, R&D/S&M changes, sales force expansion date, and specific regulatory submission and review expectations) that can shift valuation assumptions, but it is still an earnings-call transcript rather than a single new filing or approval.
Market effects
Reinforces competitive intensity in inhaled prostacyclin for PAH/related indications and highlights how device-formulation strategy (DPI vs nebulized) can drive near-term revenue mix.
No clear regional-specific catalyst beyond U.S. quantity weakness and international offset in Remodulin.
Moderate, as the 2027 approval cadence and xenotransplantation facility buildout are company-specific but can influence sentiment toward rare pulmonary disease and organ-alternative platforms.
Counterpoint
The $4B 2027 run-rate path is described as achievable but narrowed, so the market may discount it if nebulized Tyvaso competitive dynamics persist longer than management assumes.
Key entities
- companyUnited Therapeutics Corporation
NASDAQ-listed biopharma focused on pulmonary arterial hypertension and pulmonary fibrosis therapies, plus xenotransplantation initiatives.
- productTyvaso DPI
Dry powder inhaler formulation referenced with strong net product sales growth in Q2 2026.
- productNebulized Tyvaso
Nebulized formulation showing an 18% YoY revenue decline driven by lower U.S. quantities sold.
- productRalinepag
Drug candidate with an NDA submitted for PAH, with potential approval targeted in 2027.
- programXenotransplantation facilities
Construction of two commercial-scale designated pathogen-free facilities in Minnesota and Texas expected to complete by end of 2026.
